Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

Close-up of a pipette dispensing liquid into a multi-well plate.

January 9, 2026 Resource

Healthcare & Life Sciences Market Update

J.P. Morgan Healthcare Conference thumbnail

February 3, 2026 Video

J.P. Morgan Healthcare Conference 2026

Private Capital Evolving Playbook Graphic

January 9, 2026 Article

Private Capital’s Evolving Playbook for Healthcare and Life Sciences

Medium angle of sparkling blue, white, and gray bokeh lights or circles.

December 18, 2025 Video

European Healthcare & Life Sciences Investor Symposium 2025

Close-up of medical records in file room at doctor's office.

December 4, 2025 Client Alert

New Health Data Lab in Germany Facilitates Secondary Use of Health Data

February 12, 2026 Webcast

DOJ Enforcement Priorities: What Pharmaceutical Companies Need to Know

Latham lawyers offer practical insights for pharmaceutical companies on mitigating enforcement risk and implementing defense strategies. MCLE credit offered.

February 4, 2026 Video

Latham in Focus: Opportunities in Digital Health’s New Frontier

What opportunities are available to digital health companies amid an evolving regulatory environment?

February 3, 2026 Video

J.P. Morgan Healthcare Conference 2026

February 3, 2026 Podcast

Drug Pricing and Market Access: Key Takeaways From 2025 and Outlook for 2026

January 26, 2026 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 64

Close-up of electrocardiogram (ECG) machine readout.

January 22, 2026

DOJ Enforcement Priorities: What Medical Device Companies Need to Know

Latham lawyers offer practical insights for medical device companies on mitigating enforcement risk and implementing defense strategies. MCLE credit offered.

January 16, 2026

Latham & Watkins M&A Leaders on the ‘Year of the Mega Deal’

Latham partners Alex Kelly and Paul Kukish, Global Co-Chairs of the firm’s M&A and Private Equity Practice, discuss the surge in global mega deal activity that propelled Latham to the top spot in 2025 M&A and private equity league tables and what’s shaping the deal landscape for 2026.

December 17, 2025

FDA’s QMSR Implementation Is Around the Corner: What Medical Device Companies Need to Know to Be Ready

Latham’s FDA practitioners discuss the new Quality Management System Regulation and what it means for medical device manufacturers, importers, and other stakeholders. MCLE credit offered.

Digitally rendered gel capsule filled with multicolor spheres.

December 16, 2025

Episode 107 — Drug Pricing and Market Access: “Think of It as a Loop” — Succeeding in an Evolving Policy Landscape

Join the Latham team and guest Mike Domanico, a veteran of the pharmaceutical industry, for insights on how organizations can not only survive, but thrive in an ever-shifting policy landscape.

Close-up of blue and white pills capsules.

December 15, 2025

Episode 106 — The FDA’s New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway

The Latham team unpacks the FDA’s recent actions on the Commissioner’s National Priority Voucher program, the plausible mechanism pathway, and biosimilars — and what they could mean for development timelines, pricing, and market access.

November 24, 2025

Episode 105 — Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Join the Latham team and guest Eliza Biedziak from Ernst & Young LLP as they discuss what to expect from a government pricing assessment, the role assessments play in compliance, and how assessments can uncover strategic opportunities.

November 03, 2025

Episode 104 — Drug Pricing and Market Access: Deep Dive on the FDA Commissioner’s National Priority Voucher Program Awards

FDA just announced nine awards under the new CNPV program, based in part on drug pricing and onshoring of manufacturing. We review the awards in detail, consider possible agency rationale, and investigate broader implications on pharmaceutical pricing, launch strategies, and market transparency.

October 02, 2025

Episode 103 — Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

The largest drug pricing conference of the year just concluded in Chicago. Join the Latham team to discuss key themes and highlights, including most favored nation pricing considerations, bona fide service fee changes, and 340B program developments.

Digitally rendered image electrocardiograph line.

July 30, 2025

Healthcare Implications of the One Big Beautiful Bill: What You Need to Know

Members of Latham’s Healthcare & Life Sciences Practice discuss impacts of the OBBB’s healthcare policy provisions. MCLE credit offered.

June 24, 2025

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

Abstract background of wires and glowing particles

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Episode 98 — Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

Shiny transparent capsule filled with colorful spheres

May 02, 2025

Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation

On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

February 25, 2025

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

One of the country’s largest healthcare conferences recently concluded in San Francisco. Join the Latham team to discuss takeaways from the conference, including AI innovation and increased dealmaking activity, and consider the policy outlook under the new Trump administration.

Our Archive

February 6, 2026 Our Work

Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering

Firm represents the underwriters in the offering by the biopharmaceutical company.

February 6, 2026 Our Work

Latham Advises on Satellos’ US$50 Million Initial US Offering

Multidisciplinary team represents the underwriters in the offering by the biotechnology company.

January 30, 2026 Our Work

Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering

January 26, 2026 Our Work

Latham & Watkins Advises Corvus Pharmaceuticals in Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

January 22, 2026 Our Work

Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock

January 22, 2026 Recognition

Innovation Leader — Haim Zaltzman

Global Vice Chair of Emerging Companies & Growth Practice recognized for crafting trend-setting transactions, such as royalty financings in the life sciences sector, and for integrating advice to clients spanning IP, data governance, financing, and commercialization.

December 1, 2025 Recognition

Top Antitrust Lawyer 2025: Joshua Holian

Honored for his strategic approach to merger control and ability to navigate complex regulatory environments.

November 20, 2025 Recognition

MVP: Latham’s Mike Morin

Partner Mike Morin, Global Chair of the Intellectual Property Litigation Practice, was named a 2025 Law360 Intellectual Property MVP for securing two jury trial victories in the past 18 months for Sarepta Therapeutics and Abbott Laboratories in major patent disputes involving their signature products.